Results 81 to 90 of about 71,560 (137)

The association between glucagon-like peptide-1 receptor agonist and rheumatoid arthritis: a population-based case-control study. [PDF]

Ther Adv Musculoskelet Dis
Israel A, Hassan F, Merzon E, Kurtam J, Awad J, Assalia M, Green I, Vinker S, Naffaa ME.   +8 more
europepmc   +1 more source

Glucagon-like peptide-1 agonists in children with obesity and type 2 diabetes. an umbrella review. [PDF]

Front Endocrinol (Lausanne)
Mirghani H, Albishi L, Alblewi SM.
europepmc   +1 more source

The Benefits and Risks of Glucagon-Like Peptide-1 Receptor Agonists on Ocular Diseases: A Narrative Review. [PDF]

Cureus
Huang JXF, Wu J, Ahmad H, Li J, Joshi S, Yousaf A, Pemminati R, Pemminati S.   +7 more
europepmc   +1 more source

Beyond Diabetes: A Review of Emerging Indications for Glucagon-Like Peptide-1 Receptor Agonists. [PDF]

Rev Cardiovasc Med
West L, Patolia H, Chapman B, Laffin L, Vest AR, Sauer AJ, Martyn T.   +6 more
europepmc   +1 more source

Glucagon-Like Peptide 1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases. [PDF]

Arthritis Rheumatol
Karacabeyli D, Lacaille D, Lu N, Xie H, Aviña-Zubieta JA.   +4 more
europepmc   +1 more source

The Influence of Glucagon-like Peptide-1 Receptor Agonists on Outcomes Following Trigger Finger Release. [PDF]

J Hand Surg Glob Online
Dameron LS, Bank NC, Raghava N, Himmelberg S, Knoll GM.   +4 more
europepmc   +1 more source

Glucagon-Like Peptide-1 Receptor Agonist Switching and Treatment Persistence in Adults Without Diabetes.

JAMA Netw Open
Xie L, Anazco D, Chancay AH, Mathew MS, Francis JM, Almandoz JP, Messiah SE.   +6 more
europepmc   +1 more source

Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov. [PDF]

Addict Behav Rep
Patil S, Jha N, Jha MK.
europepmc   +1 more source